VC-backed Aclaris goes public

By Iris Dorbian — 4 months ago

Malvern, Pennsylvania-based Aclaris Therapeutics, a dermatology-focused specialty pharmaceutical company, has raised $55 million for its IPO after pricing its 5 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “ACRS.” Jefferies LLC and Citigroup Global Markets Inc are serving as the lead underwriters. Aclaris is backed by Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures

Continue

Kyruus nabs $25 mln

By Iris Dorbian — 5 months ago

Boston-based Kyruus, an enterprise software solutions provider that helps hospitals optimize patient access and referral management, has secured $25 million in funding. New Leaf Venture Partners led the round with participation from Providence Health & Services, Leerink Capital Partners, McKesson Ventures, Venrock, Highland Capital Partners, Lux Capital and Fidelity Biosciences.

Continue

Ivenix nabs $42 mln

By Iris Dorbian — 5 months ago

Ivenix Inc, which is developing an infusion management system for hospitals, has secured $42 million in funding. WuXi Healthcare Ventures led the round with participation from investors that included Cardinal Partners, CICA Inc, Easterly Ventures, Fidelity Biosciences and SCP Vitalife Partners. Leerink Partners served as the placement agent.

Continue

New Leaf Venture Partners leads Series B round for Unum Therapeutics

By Iris Dorbian — 8 months ago

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

Continue

Regenxbio racks up $70.5 mln Series D

By Iris Dorbian — 9 months ago

Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.

Continue

Denali launches with $217 mln

By Iris Dorbian — 9 months ago

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.

Continue

Precision BioSciences raises $25.6 mln

By Luisa Beltran — 9 months ago

Precision BioScience said Monday it closed a $25.6 million Series A round led by venBIO. Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two well-known public market investors also participated. Research Triangle Park, North Carolina-based Precision BioSciences is a genome editing company.

Continue

Symbiomix Therapeutics racks up $41 mln

By Iris Dorbian — 9 months ago

Newark, New Jersey-based Symbiomix Therapeutics, which develops medicines for serious women’s health infections, has received the final tranche of its $41 million Series A round. The investors included OrbiMed, Fidelity BioSciences and HBM Partners.

Continue

Dimension Therapeutics nets $65 mln Series B

By Iris Dorbian — 10 months ago

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Continue

Quartet Health snags $7 mln

By Iris Dorbian — 10 months ago

New York-based tech company Quartet Health has secured $7 million in funding. Annie Lamont of Oak HC/FT led the round with participation from other investors that included participation from Shulman Ventures, Fidelity Biosciences and Polaris Partners. In conjunction with the funding, Lamont has been added to Quartet Health’s board of directors.

Continue

Semma Therapeutics nets $44 mln

By Iris Dorbian — 11 months ago

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

Continue

TraceLink rakes in $20 mln

By Iris Dorbian — 12 months ago

Wakefield, Massachusetts-based TraceLink, a provider of patient safety solutions for life sciences, has closed $20 million in funding. Volition Capital led the round with participation from other investors that included Fidelity Biosciences and FirstMark Capital.

Continue

Innovent Biologics grabs $100 mln Series C

By Iris Dorbian — 1 year ago

Chinese biopharmaceutical firm Innovent Biologics has closed $100 million in Series C funding. Legend Capital led the round with participation from other backers that included Temasek, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures.

Continue

Iora Health picks up $28 mln

By Iris Dorbian — 1 year ago

Cambridge, Massachusetts-based healthcare firm Iora Health has raised $28 million in Series C funding. The investors included Foundation Medical Partners, Rice Management Company, GE Ventures, Khosla Ventures, .406 Ventures, Fidelity Biosciences and Polaris Partners.

Continue

Regenxbio picks up $30 mln Series C

By Iris Dorbian — 1 year ago

Regenxbio, a gene therapy biotech firm, has closed $30 million in Series C funding. Venrock and Brookside Capital led the round with participation from others investors that included Deerfield Management, FoxKiser and Fidelity BioSciences. Also, Camille Samuels, a partner at Venrock and Michael Gelman have been added to Regenxbio’s board of directors.

Continue

Surface Oncology attracts $35 mln Series A

By Iris Dorbian — 1 year ago

Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.

Continue